| 简介 |
FIELD : medicine, pharmaceutics.SUBSTANCE : invention refers to new compounds of the following general formula[1a], wherein Rrepresents (1) a hydrogen atom, (2) C-Calkyl group, (3) C-Calkenyl group, (4) C-Calkynyl group, (5) C-Calkoxygroup, (6) hydroxyC-Calkyl group, (7) C-Calkoxy(C-C)alkyl group, (8) -CONRR, wherein Rand Rare identical or different, and each represents a hydrogen atom or C-Calkyl group, (9) phenyl group or (10) a five-member heteroaryl group which contains at least one heteroatom specified in a group consisting of a nitrogen atom and oxygen atom, and which may be substituted by C-Calkyl group; Rrepresents (1) a halogen atom, (2) C-Calkyl group, (3) hydroxy group or (4) C-Calkoxy group; p is equal to 0, 1, 2 or 3; X represents a carbon atom or nitrogen atom; m1 is equal to 0, 1 or 2; m2 is equal to 0 or 1; the spiro ring AB may be substituted by 1-5 identical or different, specified in a group consisting of (1) hydroxy group, (2) C-Calkyl group, (3) C-Calkoxygroup and (4) oxo group; n1 is equal to 0, 1, 2, 3 or 4; n2 is equal to 1, 2, 3 or 4; n3 is equal to 0, 1 or 2, provided n2+n3 is equal to 2, 3 or 4; and a bond presented by the symbolmeans a single bond or a double bond, provided the three adjoining carbon atoms forms no allene bond presented by formula : C=C=C, or a pharmaceutically acceptable salt thereof.EFFECT : invention refers to a pharmaceutical composition possessing GPR40 agonist activity, to a GPR40 agonist drugs; to a hypoglycemic agent stimulating insulin secretion on the basis of the above compounds.45 cl, 42 tbl, 120 ex |
客服热线：
手机版
二维码
